In the Pfizer phase 3 RSV vaccine trial, three inflammatory neurologic events were initially identified within 42 days after vaccination, all in the vaccine arm: Guillain-Barré syndrome 14 days after vaccination, Miller Fisher syndrome 10 days after vaccination, and undifferentiated motor-sensory axonal polyneuropathy 21 days after vaccination.
Notes on verification
Confirmed by FDA briefing document, NEJM phase 3 trial publication, and CDC ACIP GRADE review, all independent and authoritative sources. [tier=silver indep_score=1.0 clusters=2 claim_tier=notable]
Sources
- Protein subunit RSV vaccines (GSK Arexvy and Pfizer ... - CDC (seed:health_and_medicine)
- https://www.fda.gov/media/167805/download (corroboration)
- https://www.nejm.org/doi/full/10.1056/NEJMoa2213836 (corroboration)